Table of Contents
ISRN Cardiology
Volume 2014, Article ID 652421, 7 pages
http://dx.doi.org/10.1155/2014/652421
Review Article

Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?

1Cardiology, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Sapienza University, Via di Grottarossa 1035-39, 00189 Rome, Italy
2I.R.C.C.S. Neuromed, Pozzilli, Italy

Received 4 October 2013; Accepted 1 December 2013; Published 6 February 2014

Academic Editors: W. Bloch, Y. Levy, P. S. Rahko, and J. S. Steinberg

Copyright © 2014 Pietro Francia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Mosterd, A. W. Hoes, M. C. de Bruyne et al., “Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study,” European Heart Journal, vol. 20, no. 6, pp. 447–455, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Mosterd and A. W. Hoes, “Clinical epidemiology of heart failure,” Heart, vol. 93, no. 9, pp. 1137–1146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Lloyd-Jones, M. G. Larson, E. P. Leip et al., “Lifetime risk for developing congestive heart failure: the Framingham Heart Study,” Circulation, vol. 106, no. 24, pp. 3068–3072, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. G. F. Cleland, I. Gemmell, A. Khand, and A. Boddy, “Is the prognosis of heart failure improving?” European Journal of Heart Failure, vol. 1, no. 3, pp. 229–241, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Squire, “Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?” Heart Failure Reviews, vol. 9, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Moss, W. J. Hall, D. S. Cannom et al., “Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia,” The New England Journal of Medicine, vol. 335, no. 26, pp. 1933–1940, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Moss, W. Zareba, W. J. Hall et al., “Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction,” The New England Journal of Medicine, vol. 346, no. 12, pp. 877–883, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. G. H. Bardy, K. L. Lee, D. B. Mark et al., “Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure,” The New England Journal of Medicine, vol. 352, no. 3, pp. 225–237, 2005. View at Google Scholar
  9. A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen et al., “ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons,” Journal of the American College of Cardiology, vol. 51, pp. e1–e62, 2008. View at Google Scholar
  10. R. Tung, P. Zimetbaum, and M. E. Josephson, “A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death,” Journal of the American College of Cardiology, vol. 52, no. 14, pp. 1111–1121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. H. Hohnloser, K. H. Kuck, P. Dorian et al., “Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2481–2488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Kadish, A. Dyer, J. P. Daubert et al., “Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2151–2158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Pitt, R. Segal, F. A. Martinez et al., “Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE),” The Lancet, vol. 349, no. 9054, pp. 747–752, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Pitt, P. A. Poole-Wilson, R. Segal et al., “Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II,” The Lancet, vol. 355, no. 9215, pp. 1582–1587, 2000. View at Google Scholar · View at Scopus
  15. J. N. Cohn and G. Tognoni, “A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure,” The New England Journal of Medicine, vol. 345, no. 23, pp. 1667–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Dickstein and J. Kjekshus, “Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,” The Lancet, vol. 360, no. 9335, pp. 752–760, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Pfeffer, J. J. V. McMurray, E. J. Velazquez et al., “Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both,” The New England Journal of Medicine, vol. 349, no. 20, pp. 1893–1906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. D. Solomon, S. Zelenkofske, J. J. V. McMurray et al., “Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both,” The New England Journal of Medicine, vol. 352, no. 25, pp. 2581–2588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Pfeffer, K. Swedberg, C. B. Granger et al., “Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme,” The Lancet, vol. 362, no. 9386, pp. 759–766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. J. V. McMurray, J. Östergren, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial,” The Lancet, vol. 362, no. 9386, pp. 767–771, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. C. B. Granger, J. J. V. McMurray, S. Yusuf et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial,” The Lancet, vol. 362, no. 9386, pp. 772–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. D. Solomon, D. Wang, P. Finn et al., “Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program,” Circulation, vol. 110, no. 15, pp. 2180–2183, 2004. View at Google Scholar
  23. H. Svanström, B. Pasternak, and A. Hviid, “Association of treatment with losartan vs candesartan and mortality among patients with heart failure,” The Journal of the American Medical Association, vol. 307, no. 14, pp. 1506–1512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Al-Gobari, C. El Khatib, F. Pillon, and F. Gueyffier, “Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials,” BMC Cardiovascular Disorders, vol. 13, article 52, 2013. View at Google Scholar
  25. “A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators,” The New England Journal of Medicine, vol. 337, no. 22, pp. 1576–1583, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. L. A. Saxon, M. R. Bristow, J. Boehmer et al., “Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial,” Circulation, vol. 114, no. 25, pp. 2766–2772, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. N. Obeyesekere, W. Chan, D. Stub et al., “Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population,” Pacing and Clinical Electrophysiology, vol. 33, no. 6, pp. 696–704, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Francia, C. Balla, A. Uccellini et al., “Low-dose angiotensin receptor blockers as an alternative to ACE-inhibitors increase the risk of appropriate ICD interventions in heart failure,” International Journal of Cardiology, vol. 145, no. 3, pp. 522–524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Mazzolai, M. Maillard, J. Rossat, J. Nussberger, H. R. Brunner, and M. Burnier, “Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists,” Hypertension, vol. 33, no. 3, pp. 850–855, 1999. View at Google Scholar · View at Scopus
  30. M. P. Maillard, G. Würzner, J. Nussberger, C. Centeno, M. Burnier, and H. R. Brunner, “Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing,” Clinical Pharmacology and Therapeutics, vol. 71, no. 1, pp. 68–76, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Yusuf, M. A. Pfeffer, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial,” The Lancet, vol. 362, no. 9386, pp. 777–781, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Konstam, J. D. Neaton, K. Dickstein et al., “Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial,” The Lancet, vol. 374, no. 9704, pp. 1840–1848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Iravanian and S. C. Dudley Jr., “The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias,” Heart Rhythm, vol. 5, no. 6, pp. S12–S17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. W. C. de Mello, “Is an intracellular renin-angiotensin system involved in control of cell communication in heart?” Journal of Cardiovascular Pharmacology, vol. 23, no. 4, pp. 640–646, 1994. View at Google Scholar · View at Scopus
  35. W. C. de Mello and M. J. Crespo, “Cardiac refractoriness in rats is reduced by angiotensin II,” Journal of Cardiovascular Pharmacology, vol. 25, no. 1, pp. 51–56, 1995. View at Google Scholar · View at Scopus
  36. W. C. de Mello, “Renin-angiotensin system and cell communication in the failing heart,” Hypertension, vol. 27, no. 6, pp. 1267–1272, 1996. View at Google Scholar · View at Scopus
  37. S. O. Marx, S. Reiken, Y. Hisamatsu et al., “PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts,” Cell, vol. 101, no. 4, pp. 365–376, 2000. View at Google Scholar · View at Scopus
  38. G. Hasenfuss, “Alterations of calcium-regulatory proteins in heart failure,” Cardiovascular Research, vol. 37, pp. 279–289, 1998. View at Google Scholar
  39. T. Tokuhisa, M. Yano, M. Obayashi et al., “AT1 receptor antagonist restores cardiac ryanodine receptor function, rendering isoproterenol-induced failing heart less susceptible to Ca2+-leak induced by oxidative stress,” Circulation Journal, vol. 70, no. 6, pp. 777–786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Flesch, F. Schiffer, O. Zolk et al., “Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca2+-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy,” Journal of Hypertension, vol. 15, no. 9, pp. 1001–1009, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. R. S. Kass and M. L. Blair, “Effects of angiotensin II on membrane current in cardiac Purkinje fibers,” Journal of Molecular and Cellular Cardiology, vol. 13, no. 9, pp. 797–809, 1981. View at Google Scholar · View at Scopus
  42. K. U. Malik and A. Nasjletti, “Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries,” Circulation Research, vol. 38, no. 1, pp. 26–30, 1976. View at Google Scholar · View at Scopus
  43. E. R. Lumbers, D. I. McCloskey, and E. K. Potter, “Inhibition by angiotensin II of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog,” The Journal of Physiology, vol. 294, pp. 69–80, 1979. View at Google Scholar · View at Scopus
  44. H. Gavras, A. F. Lever, J. J. Brown, R. F. Macadam, and J. I. Robertson, “Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II,” The Lancet, vol. 2, no. 7714, pp. 19–22, 1971. View at Google Scholar · View at Scopus
  45. F. Kieken, N. Mutsaers, E. Dolmatova et al., “Structural and molecular mechanisms of gap junction remodeling in epicardial border zone myocytes following myocardial infarction,” Circulation Research, vol. 104, no. 9, pp. 1103–1112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. A. A. Sovari, S. Iravanian, E. Dolmatova et al., “Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death,” Journal of the American College of Cardiology, vol. 58, no. 22, pp. 2332–2339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Iravanian, A. A. Sovari, H. A. Lardin et al., “Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43,” Journal of Molecular Medicine, vol. 89, no. 7, pp. 677–687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Cosentino, C. Savoia, P. de Paolis et al., “Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists,” American Journal of Hypertension, vol. 18, no. 4, pp. 493–499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Kaschina, A. Grzesiak, J. Li et al., “Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?” Circulation, vol. 118, no. 24, pp. 2523–2532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. G. P. Thomas, G. R. Ferrier, and S. E. Howlett, “Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion,” The Journal of Pharmacology and Experimental Therapeutics, vol. 278, no. 3, pp. 1090–1097, 1996. View at Google Scholar · View at Scopus